Transcutaneous Spinal Cord Stimulation for Spasticity in Primary Lateral Sclerosis: A Case Series.

J Neurol Phys TherMay 4, 2026 (epub)
Case ReportNeurologyPhysical Medicine & Rehabilitation

Kayla Chomko, Lauren Tabor Gray, Alan V Boruch et al.

✦ AI-curated · Sources linked

Case in brief

This case series involved six participants with primary lateral sclerosis (PLS) who underwent a single 30-minute session of transcutaneous spinal cord stimulation (tSCS). Assessments before and after the intervention showed improvements in spasticity, as measured by the Modified Ashworth Scale, and functional mobility, as indicated by the Tinetti Performance Oriented Mobility Assessment. Five participants reported reduced spasticity on the Numerical Rating Scale, with no adverse events noted.

Diagnostic / clinical pearl

Transcutaneous spinal cord stimulation may offer a nonpharmacological approach to reduce spasticity and improve mobility in patients with primary lateral sclerosis.

Source

PubMed · PMID 42071279

Published in J Neurol Phys Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.